China is the “leader in liver diseases” in the world, with as many as 400 million patients with various liver diseases, of which more than 30 million patients develop chronic hepatitis/liver fibrosis, up to 7 million patients have cirrhosis, and 300,000-500,000 patients progress to liver failure, leading to a high mortality from liver diseases in China.
Shanghai Celliver Biotechnology Co., Ltd. was established in Zhangjiang High-tech Park in 2013, rooted in the field of cell and regenerative medicine, focusing on developing life-saving cell therapies, and is committed to becoming a worldwide pioneer company leading cell-based treatment for many medically refractory liver diseases including NASH, cirrhosis and end-stage liver diseases.
1. An efficient approach for expansion and differentiation of human hepatocyte-derived liver progenitor-like cells (HepLPCs) in vitro that provide a novel cell source for the treatment of liver diseases (Cell Research 2017, 2018);
2. A novel extracorporeal liver support device embedded with 3D-layered human iHepLPCs (Aliver-BAL) that exhibited a remarkable capacity to support liver function in vitro and promote liver regeneration in vivo. (Science Translational Medicine 2020)
